ALDX Logo

Aldeyra Therapeutics, Inc. (ALDX) 

NASDAQ
Market Cap
$320.88M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
72 of 776
Rank in Industry
57 of 433

Largest Insider Buys in Sector

ALDX Stock Price History Chart

ALDX Stock Performance

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in …

Insider Activity of Aldeyra Therapeutics, Inc.

Over the last 12 months, insiders at Aldeyra Therapeutics, Inc. have bought $2.77M and sold $851,621 worth of Aldeyra Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aldeyra Therapeutics, Inc. have bought $12.36M and sold $2.65M worth of stock each year.

Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (10 percent owner) — $41.53M.

The last purchase of 37,712 shares for transaction amount of $178,755 was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2024‑04‑05.

List of Insider Buy and Sell Transactions, Aldeyra Therapeutics, Inc.

2024-08-12SaleChief Development Officer
16,041
0.0272%
$4.74$75,975+14.32%
2024-08-12SaleSee Remarks
10,834
0.0184%
$4.74$51,313+14.32%
2024-04-05Purchase10 percent owner
37,712
0.0643%
$4.74$178,755-11.65%
2024-04-04Purchase10 percent owner
140,281
0.2374%
$4.67$655,112-10.90%
2024-04-03Purchase10 percent owner
309,847
0.5185%
$4.09$1.27M+0.60%
2024-04-02Purchase10 percent owner
186,051
0.3061%
$3.44$640,015+17.46%
2024-04-01Purchase10 percent owner
8,374
0.0141%
$3.25$27,216+27.52%
2024-03-12SalePresident and CEO
85,324
0.147%
$3.05$260,238+37.21%
2024-03-12SaleChief Development Officer
11,537
0.0206%
$3.16$36,503+37.21%
2024-03-11SalePresident and CEO
97,914
0.1675%
$3.27$320,521+26.46%
2024-03-11SaleChief Development Officer
18,231
0.0324%
$3.41$62,102+26.46%
2024-03-11SaleSee Remarks
13,201
0.0235%
$3.41$44,968+26.46%
2023-10-18Sale10 percent owner
306,499
0.5276%
$1.74$533,308+109.83%
2023-10-16Sale10 percent owner
2.45M
3.6657%
$1.60$3.92M+98.09%
2023-04-12Purchasedirector
509
0.0009%
$10.13$5,156
2022-08-09Purchase
15,000
0.027%
$7.85$117,750-4.83%
2022-08-08Purchase
97,000
0.1669%
$7.24$702,280-1.53%
2022-08-05Purchase
141,000
0.2422%
$6.95$979,950+2.46%
2022-08-04Purchase
95,100
0.1609%
$6.17$586,767+13.46%
2022-08-03Purchase
100,000
0.1722%
$5.84$584,000+21.64%

Insider Historical Profitability

18.59%
PERCEPTIVE ADVISORS LLC10 percent owner
9275851
15.6102%
$5.40182+4.58%
Brady Todd CPresident and CEO
1471298
2.476%
$5.40112+8.55%
EDELMAN JOSEPH
11350085
19.1009%
$5.4090+19.29%
DOUGLAS RICHARDdirector
125000
0.2104%
$5.4070+43%
Reed JoshuaChief Financial Officer
35774
0.0602%
$5.4010+5.74%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Perceptive Advisors$28.1M14.468.59M0%+$00.02
Tupelo Capital Management LLC$17.9M9.225.48M0%+$00.44
The Vanguard Group$12.65M6.513.87M-1.49%-$191,353.86<0.0001
BlackRock$10.83M5.573.31M-3.5%-$392,357.51<0.0001
Kennedy Capital Management Inc$4.31M2.221.32M+3.29%+$137,369.430.09
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.